Literature DB >> 35213019

Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts.

Nerea Moreno1,2,3, Irene González-Martínez1,2,3, Rubén Artero4,5,6, Estefanía Cerro-Herreros1,2,3.   

Abstract

Western blot assays are not adequate for high-throughput screening of protein expression because it is an expensive and time-consuming technique. Here we demonstrate that quantitative dot blots in plate format are a better option to determine the absolute contents of a given protein in less than 48 h. The method was optimized for the detection of the Muscleblind-like 1 protein in patient-derived myoblasts treated with a collection of more than 100 experimental oligonucleotides.
© 2022. The Author(s).

Entities:  

Keywords:  DM1 myoblasts; Muscleblind-like protein 1; Myotonic dystrophy; Oligonucleotides; Quantitative dot blot

Mesh:

Substances:

Year:  2022        PMID: 35213019     DOI: 10.1007/978-1-0716-2010-6_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  RNA-Targeted Therapeutics.

Authors:  Stanley T Crooke; Joseph L Witztum; C Frank Bennett; Brenda F Baker
Journal:  Cell Metab       Date:  2019-02-05       Impact factor: 27.287

2.  Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons.

Authors:  Hong Jiang; Ami Mankodi; Maurice S Swanson; Richard T Moxley; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2004-10-20       Impact factor: 6.150

Review 3.  Therapeutic Oligonucleotides: State of the Art.

Authors:  C I Edvard Smith; Rula Zain
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-09       Impact factor: 13.820

4.  Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise.

Authors:  Christopher M Chamberlain; Laura P W Ranum
Journal:  Hum Mol Genet       Date:  2012-07-30       Impact factor: 6.150

5.  Quantitative dot blot analysis (QDB), a versatile high throughput immunoblot method.

Authors:  Geng Tian; Fangrong Tang; Chunhua Yang; Wenfeng Zhang; Jonas Bergquist; Bin Wang; Jia Mi; Jiandi Zhang
Journal:  Oncotarget       Date:  2017-04-19

6.  Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.

Authors:  Ludovic Arandel; Micaela Polay Espinoza; Magdalena Matloka; Audrey Bazinet; Damily De Dea Diniz; Naïra Naouar; Frédérique Rau; Arnaud Jollet; Frédérique Edom-Vovard; Kamel Mamchaoui; Mark Tarnopolsky; Jack Puymirat; Christophe Battail; Anne Boland; Jean-Francois Deleuze; Vincent Mouly; Arnaud F Klein; Denis Furling
Journal:  Dis Model Mech       Date:  2017-02-10       Impact factor: 5.758

Review 7.  Consensus-based care recommendations for adults with myotonic dystrophy type 1.

Authors:  Tetsuo Ashizawa; Cynthia Gagnon; William J Groh; Laurie Gutmann; Nicholas E Johnson; Giovanni Meola; Richard Moxley; Shree Pandya; Mark T Rogers; Ericka Simpson; Nathalie Angeard; Guillaume Bassez; Kiera N Berggren; Deepak Bhakta; Marco Bozzali; Ann Broderick; Janice L B Byrne; Craig Campbell; Edith Cup; John W Day; Elisa De Mattia; Denis Duboc; Tina Duong; Katy Eichinger; Anne-Berit Ekstrom; Baziel van Engelen; Belen Esparis; Bruno Eymard; Marla Ferschl; Shahinaz M Gadalla; Benjamin Gallais; Todd Goodglick; Chad Heatwole; James Hilbert; Venessa Holland; Marie Kierkegaard; Wilma J Koopman; Kari Lane; Daphne Maas; Ami Mankodi; Katherine D Mathews; Darren G Monckton; David Moser; Saman Nazarian; Linda Nguyen; Peg Nopoulos; Richard Petty; Janel Phetteplace; Jack Puymirat; Subha Raman; Louis Richer; Elisabetta Roma; Jacinda Sampson; Valeria Sansone; Benedikt Schoser; Laurie Sterling; Jeffrey Statland; S H Subramony; Cuixia Tian; Careniña Trujillo; Gordon Tomaselli; Chris Turner; Shannon Venance; Aparajitha Verma; Molly White; Stefan Winblad
Journal:  Neurol Clin Pract       Date:  2018-12

8.  miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.

Authors:  Estefania Cerro-Herreros; Maria Sabater-Arcis; Juan M Fernandez-Costa; Nerea Moreno; Manuel Perez-Alonso; Beatriz Llamusi; Ruben Artero
Journal:  Nat Commun       Date:  2018-06-26       Impact factor: 14.919

9.  Disease burden of myotonic dystrophy type 1.

Authors:  Erik Landfeldt; Nikoletta Nikolenko; Cecilia Jimenez-Moreno; Sarah Cumming; Darren G Monckton; Grainne Gorman; Chris Turner; Hanns Lochmüller
Journal:  J Neurol       Date:  2019-02-20       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.